Virtual Evolution of HVEM Segment for Checkpoint Inhibitor Discovery.
Virtual Evolution of HVEM Segment for Checkpoint Inhibitor Discovery.
复制标题
用于检查点抑制剂发现的 HVEM 部分的虚拟演化
DOI:
10.3390/ijms22126638
复制
发表时间:
2021-06-21
影响因子:
5.6
通讯作者:
Xue S
中科院分区:
文献类型:
--
作者:
Yu M;Zhao H;Miao Y;Luo SZ;Xue S
Immune therapy has emerged as an effective treatment against cancers. Inspired by the PD-1/PD-L1 antibodies, which have achieved great success in clinical, other immune checkpoint proteins have drawn increasing attention in cancer research. B and T lymphocyte attenuator (BTLA) and herpes virus entry mediator (HVEM) are potential targets for drug development. The co-crystal structure of BTLA/HVEM have revealed that HVEM (26–38) fragment is the core sequence which directly involved on the interface. Herein, we conducted virtual evolution with this sequence by using saturation mutagenesis in silico and mutants with lower binding energy were selected. Wet-lab experiments confirmed that several of them possessed higher affinity with BTLA. Based on the best mutant of the core sequence, extended peptides with better efficacy were obtained. Furthermore, the mechanism of the effects of mutations was revealed by computational analysis. The mutated peptide discovered here can be a potent inhibitor to block BTLA/HVEM interaction and its mechanism may extend people’s view on inhibitor discovery for the checkpoint pair.
登录
查看更多内容
DOI:
10.1016/j.str.2020.07.013
发表时间:
2020-11-03
期刊:
Structure (London, England : 1993)
影响因子:
--
作者:
Shrestha R;Garrett-Thomson SC;Liu W;Almo SC;Fiser A
通讯作者:
Fiser A
影响因子:
5.6
作者:
de Jong FC;Rutten VC;Zuiverloon TCM;Theodorescu D
通讯作者:
Theodorescu D
DOI:
10.1073/pnas.0902115106
发表时间:
2009-04-14
影响因子:
11.1
作者:
Cheung, Timothy C.;Steinberg, Marcos W.;Ware, Carl F.
通讯作者:
Ware, Carl F.
影响因子:
16
作者:
Carfí, A;Willis, SH;Wiley, DC
通讯作者:
Wiley, DC
影响因子:
7.2
作者:
Gertner-Dardenne J;Fauriat C;Olive D
通讯作者:
Olive D